Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03982160 · ClinicalTrials.gov registry record · Phase 4
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
A Phase 4 study of Chronic Kidney Disease, sponsored by The University of Texas at Arlington.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT03982160 is a Phase 4 study of Chronic Kidney Disease that is actively recruiting participants, run by The University of Texas at Arlington. The registered enrollment target is 15 participants, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03982160, a Phase 4 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by The University of Texas at Arlington.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future cardiovascular events in these patients. . The goal of this study is to determine whether overcoming the accumulation of endogenous ADMA with acute L-arginine infusion reduces SNA in CKD patients.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG L-Arginine
Study Locations (2)
Delaware
- University of Delaware - Newark
Texas
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03982160
The ClinicalTrials.gov registry entry for NCT03982160 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,207-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (100% lower). The listed sponsor is The University of Texas at Arlington, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03982160 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Delaware, Texas.
Frequently Asked Questions
What is clinical trial NCT03982160 about?
NCT03982160 is a clinical study titled "L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients". Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve acti...
What is the current status of trial NCT03982160?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2018-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03982160 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT03982160?
The interventions under investigation include: Placebo (OTHER), L-Arginine (DRUG).
Who is sponsoring clinical trial NCT03982160?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03982160 being conducted?
This trial has 2 study locations across Delaware, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
Empagliflozin Treatment in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)
COMPLETED · Phase 4
-
Dialysis Clinical Outcomes Revisited (DCOR) Trial
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.